Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency

Background: Once-weekly TransCon hGH (lonapegsomatropin) is an investigational long-acting prodrug of somatropin in development for GHD. In the pivotal 52-week phase 3 heiGHt trial, lonapegsomatropin demonstrated superior annualized height velocity (AHV) compared to the same weekly dose of daily som...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Endocr Soc
Auteurs principaux: Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Hofman, Paul, Saenger, Paul, Chertok, Elena, Aghajanova, Elena M, Song, Wenjie, Mao, Meng, Chessler, Steven D, Komirenko, Allison, Beckert, Michael, Shu, Aimee D, Thornton, Paul S
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2021
Sujets:
Pediatric Endocrinology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090180/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1378
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires